Eric Morand

MONASH UNIVERSITY

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Collaborators (10)

Zahi Touma

University Health Network

Ian N Bruce

The University of Manchester

UNITED KINGDOM

Julie Stout

MONASH UNIVERSITY

Roy Fleischmann

Clinical Professor of Medicine

University of Texas Southwestern Medical Center

UNITED STATES

Ronald van Vollenhoven

Professor and Chief

Amsterdam UMC

Anca D. Askanase

Columbia University Irving Medical Center

UNITED STATES

Rangi Kandane-Rathnayake

MONASH UNIVERSITY

Luís Sousa Inês

Assistant Professor

University of Coimbra

Victoria P. Werth

UNITED STATES

Sarah Jones

MONASH UNIVERSITY

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eric Morand

Research Interests

Explore related searches

Contact this professor

Articles (21)

Collaborators (10)

Zahi Touma

Ian N Bruce

Julie Stout

Roy Fleischmann

Ronald van Vollenhoven

Anca D. Askanase

Rangi Kandane-Rathnayake

Luís Sousa Inês

Victoria P. Werth

Sarah Jones

Make your next move.

Eric Morand

Research Interests

Explore related searches

Contact this professor

Articles (21)

Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus

10 years in lupus – progress, but not enough

Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria

Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)

Pregnancy outcomes in Australian patients with systemic lupus erythematosus

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned

Flare in Systemic Lupus Erythematosus: Lost in Translation?

Predictors of Organ Damage in Systemic Lupus Erythematosus in the Asia Pacific Region: A Systematic Review

TYK2: an emerging therapeutic target in rheumatic disease

Anti‐MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease

Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective

Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials

Utility of repeat extractable nuclear antigen antibody testing: a retrospective audit

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Clinical associations of cognitive dysfunction in systemic lupus erythematosus

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature

Collaborators (10)

Zahi Touma

Ian N Bruce

Julie Stout

Roy Fleischmann

Ronald van Vollenhoven

Anca D. Askanase

Rangi Kandane-Rathnayake

Luís Sousa Inês

Victoria P. Werth

Sarah Jones

Make your next move.